PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE

Abstract

Abstract Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Lymphomas are a heterogeneous group of malignancies of lymphocytes that develop as a result of abnormal clonal proliferation of B lymphocytes, T lymphocytes or natural killer cells. Kindlins are a group of focal adhesion proteins involved in the activation of integrins. It has three members as kindlin-1, kindlin-2, and kindlin-3. Kindlin-3 is a protein in the kindlin protein family that regulates the functions of integrins by binding to the cytoplasmic part of the integrin beta chain. The result of kindlin-mediated integrin activation and integrin-ligand binding is cell adhesion, proliferation and migration, extracellular matrix aggregation, cell survival, proliferation and differentiation. It is mainly synthesized from hematopoietic cells. The close relationship between integrins and cancer pathogenesis has led to the investigation of the role of kindlins in cancers. Aims: Our study was designed to evaluate the effect of serum kindlin-3 level on disease susceptibility, treatment response and febrile neutropenia in newly diagnosed non-Hodgkin (NHL) and Hodgkin lymphoma (HL) patients. Methods: Patients who applied to Istanbul Training and Research Hospital, Hematology Clinic between May 2021 and September 2021 were included in the study. Forty-five patients were diagnosed with lymphoma (NHL and HL); 2 patients were excluded from the study. At the time of diagnosis, blood samples were taken into gel serum tubes and then their serum samples were obtained by centrifugation and stored at -80 ℃. Results: Thirty-four NHL and 9 HL, a total of 43 patients (29 M and 14 F) and 41 healthy controls (16 M and 25 F) were included in the study. Serum kindlin-3 levels were compared between patients and healthy controls. The mean serum kindlin-3 level was found to be statistically higher in healthy controls compared to patients (patients: 2.9±4, healthy controls: 10.42±7, p<0.001). According to the ROC analysis, serum kindlin-3 cut-off of 2.928 was found to be a statistically significant parameter in predicting the disease (AUC: 0.905, 95% CI: 0.838-0.972, p<0.05). There was no statistically significant effect on patients’ interim or end-of-treatment response or development of febrile neutropenia during their follow-up. Summary/Conclusion: The results suggest that kindlin-3 molecule can be considered as a possible biomarker in the etiopathogenesis of lymphoma. Graphic1. The ROC analysis: Serum kindlin-3 cut-off of 2.928 Keywords: Non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, Prognosis